Jeremy Middleton

Jeremy Middleton is an accomplished executive with over 30 years of US and international experience in
corporate development, strategic planning and operations for both large and entrepreneurial
pharmaceutical and biotechnology companies. He previously served as Vice President of Corporate
Development for Elusys Therapeutics, a biopharmaceutical company focused on monoclonal antibody-
based therapeutics to treat infectious diseases, which developed and won FDA, EU and Health Canada
approval for Anthim, a medical countermeasure against anthrax toxin. Prior to that he served in senior
executive roles leading commercial efforts at rapid-growth specialty companies Valera Pharmaceuticals
(which developed hydrogel polymer implant technology) and Neose Technologies (which developed
protein therapeutics, including long-acting G-CSF). Before joining Neose, he held leadership positions in
immunology and oncology at BASF Pharma and Abbott Laboratories, including serving as Global Product
Director of Humira and spearheading the strategic planning and business development efforts which
precipitated the sale of BASF Pharma. Earlier in his career, Mr. Middleton held management positions of
increasing responsibility at Boots Pharmaceuticals in Europe, Australia, Southeast Asia and the US,
where he led numerous initiatives to reengineer pharmaceutical manufacturing facilities and operations
in major markets. He has extensive experience in building and leading multifunctional teams and an
impressive track record of driving growth for brands such as Synthroid, Vicodin, Vicoprofen, Dilaudid,
and Vantas among others. He has been a key contributor to successful exits for several small and mid-
sized biopharma companies.

Mr. Middleton has deep expertise in managing public-private partnerships, raising capital and securing
non-dilutive funding through US federal (NIH, BARDA, DOD) and foreign (Health Canada) government
agencies. He has served as a board member on the Alliance for Biosecurity and on the Infrastructure
Advisory Committee of the NJ Office of Homeland Security and Preparedness.